New US-UK Trade Deal Could Lead to Over 200,000 Avoidable Deaths Due to NHS Funding Cuts

A new trade agreement between the United States and the United Kingdom may have dire consequences for public health in England, potentially resulting in over 200,000 avoidable deaths. This grim forecast stems from an analysis suggesting that the deal could divert billions of pounds from critical healthcare services, ultimately harming the UK's National Health Service (NHS). In December, the UK government reached an agreement with Washington, committing to increase spending on new medicines from 0.3% of GDP to at least 0.6% over the next decade. The trade deal, intended to avoid punitive tariffs that had been threatened by then-President Donald Trump, would not impose levies on British exports of pharmaceutical products and medical devices for at least the next three years. Trump's threats included potential tariffs of up to 100% on some medicines imported into the US, which heightened the urgency of securing a trade agreement. According to an analysis published in The British Medical Journal (BMJ), a peer-reviewed publication, the deal is projected to cost the NHS an additional £45 billion to £60 billion by 2036 to finance the increased expenditure on new medicines. The authors of the analysis hail from notable institutions, including the University of York and the University of Liverpool, in addition to Christchurch Hospital in New Zealand. The study highlights a critical flaw in publicly funded health systems: when budgets are finite, increased spending in one area invariably forces cuts in others. Unless the UK government allocates additional funding to the NHS, redirecting resources to pay for the new medicines could inadvertently contribute to approximately 229,000 extra deaths. This trend is likely to exacerbate existing health inequalities, disproportionately impacting individuals suffering from heart and respiratory conditions, gastrointestinal diseases, and cancer. The UK’s Department of Health and Social Care, along with the Department for Business and Trade, did not immediately respond to requests for comment regarding the analysis. While the UK government has lauded the trade deal, claiming it will ensure access to medicines and stimulate vital investments in the UK patient care and business sectors, the analysis presents a contrasting view. It argues that the assumption that avoiding Trump’s threatened tariffs will yield economic benefits for the UK is fundamentally misguided. The authors further note that the UK continues to be a net importer of medicines, meaning a large portion of the increased costs will benefit multinational pharmaceutical manufacturers rather than being reinvested into the NHS or the broader UK economy. By 2031, the analysis warns that the projected costs of the trade deal could surpass the total annual value of UK pharmaceutical exports to the US. As the UK navigates this critical juncture in its healthcare financing and international trade, the implications of the US-UK trade deal merit close scrutiny. Stakeholders and policymakers are urged to consider the potential short- and long-term health impacts as they make decisions that could affect the lives of thousands of citizens. Related Sources: • Source 1 • Source 2